logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Sayed M.S. Hashemi

department of pulmonary medicine
H指数:23
被引数:2,212

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study

确定识别奥希康替尼耐药性的最佳方法；OSIRIS研究中的奥希康替尼一线治疗队列

Lung Cancer
IF4.4
2025-09-280
PRE
J.W.T. van der Wel; S.M. Ernst; M. Jebbink; D. van den Broek; S.K. Badrising; L.C. Steinbusch; G. Ruiter; W.S.M.E. Theelen; B.A.M.H. van Veggel; J. Smit; A.M. Dingemans; M.S. Paats; H.J. Dubbink; S.M.S. Hashemi; T. Radonic; D. Cohen; A.J. van der Wekken; A. ter Elst; W. Timens; L.E. Hendriks; E.J.M. Speel; M.M.J. Disselhorst; A. Welling; F. van der Meer; L.J.W. Bosch; K. Monkhorst; M.C. Boelens; E.F. Smit; A.J. de Langen
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib

循环肿瘤DNA在晚期EGFRex20+ NSCLC中的研究：与组织活检的一致性、疗效监测及对高剂量奥希替尼耐药性的分析

Targeted Oncology
IF4
2025-06-050
OAAI
Fenneke Zwierenga; M. Benthe Muntinghe-Wagenaar; Pim Rozendal; Adrianus J. de Langen; Lizza E. L. Hendriks; Michel van den Heuvel; Cor van der Leest; Sayed M. S. Hashemi; Paul van der Leest; T. Jeroen N. Hiltermann; Ed Schuuring; Anthonie J. van der Wekken
Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance

结合循环肿瘤DNA和肿瘤组织的分子联合分析以识别奥希替尼耐药性

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
van der Wel, T.; Jebbink, M.; Badrising, S.; Steinbusch, L.; Ruiter, G.; Theelen, W. S. M. E.; Veggel, B. V.; Smit, J.; Hashemi, S.; Van Der Wekken, A. J.; Hendriks, L. E.; Paats, M. S.; Ernst, S.; Van Den Broek, D.; Bosch, L. J. W.; Monkhorst, K.; Smit, E. F.; Boelens, M. C.; De langen, A. J.
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer

阿法替尼联合西妥昔单抗治疗EGFR外显子20插入阳性非小细胞肺癌的2期临床试验

CANCER
IF5.1
2023-10-312
OAAI
van Veggel, Bianca A. M. H.; van der Wekken, Anthonie J.; Paats, Marthe S.; Hendriks, Lizza E. L.; Hashemi, Sayed M. S.; Daletzakis, Antonios; van den Broek, Daan; Bosch, Linda J. W.; Monkhorst, Kim; Smit, Egbert F.; de Langen, Adrianus J.
Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
ANNALS OF ONCOLOGY
IF65.4
2023-10-011
PRE
Verkerk, K.; van der Wel, T.; Zeverijn, L. J.; Geurts, B. S.; Spiekman, I. A. C.; de Wit, G. F.; Roepman, P.; Jansen, A.; van der Noort, V.; Smit, E. F.; Hoeben, A.; Hendriks, L.; Van Herpen, C. M. L.; Piet, B.; Herder, G.; Hashemi, S. M. S.; Gelderblom, H.; Verheul, H. M. W.; Voest, E. E.; De langen, J.
Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors
EUROPEAN JOURNAL OF CANCER
IF7.1
2023-04-0112
OAAI
Tohidinezhad, Fariba; Bontempi, Dennis; Zhang, Zhen; Dingemans, Anne-Marie; Aerts, Joachim; Bootsma, Gerben; Vansteenkiste, Johan; Hashemi, Sayed; Smit, Egbert; Gietema, Hester; Aerts, Hugo J. W. L.; Dekker, Andre; Hendriks, Lizza E. L.; Traverso, Alberto; De Ruysscher, Dirk
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

曲妥珠单抗-Emtansine和奥希替尼联合治疗靶向EGFR突变阳性NSCLC的HER2旁路耐药

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2023-04-0115
OA
Jebbink, M.; de Langen, A. J.; Monkhorst, K.; Boelens, M. C.; van den Broek, D.; van der Noort, V.; de Gooijer, C. J.; Mahn, M.; van der Wekken, A. J.; Hendriks, L.; Hashemi, S. M. S.; Paats, M. S.; Dingemans, A. C.; Smit, E. F.
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
FRONTIERS IN ONCOLOGY
IF3.3
2023-03-095
OAAI
Meertens, Marinda; Muntinghe-Wagenaar, M. Benthe; Sikkema, Barend J.; Lopez-Yurda, Marta; Retel, Valesca P.; Paats, Marthe S.; Ter Heine, Rob; Schuuring, Ed; Timens, Wim; Touw, Daan J.; van Boven, Job F. M.; de Langen, Adrianus. J.; Hashemi, Sayed M. S.; Hendriks, Lizza E. L.; Croes, Sander; van den Heuvel, Michel M.; Dingemans, Anne-Marie C.; Mathijssen, Ron H. J.; Smit, Egbert F.; Huitema, Alwin D. R.; Steeghs, Neeltje; van der Wekken, Anthonie J.
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

卡马替尼在MET外显子14突变的非小细胞肺癌 (RECAP) 中的实际经验: 来自早期访问计划的回顾性分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-06-1317
OAAI
Illini, Oliver; Fabikan, Hannah; Swalduz, Aurelie; Vikstrom, Anders; Krenbek, Dagmar; Schumacher, Michael; Dudnik, Elizabeth; Studnicka, Michael; Ohman, Ronny; Wurm, Robert; Wannesson, Luciano; Peled, Nir; Kian, Waleed; Bar, Jair; Daher, Sameh; Addeo, Alfredo; Rotem, Ofer; Pall, Georg; Zer, Alona; Saad, Akram; Cufer, Tanja; Sorotsky, Hadas Gantz; Hashemi, Sayed M. S.; Mohorcic, Katja; Stoff, Ronen; Rovitsky, Yulia; Keren-Rosenberg, Shoshana; Winder, Thomas; Weinlinger, Christoph; Valipour, Arschang; Hochmair, Maximilian J.
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
ANNALS OF ONCOLOGY
IF65.4
2022-04-010
OA
Dafni, U.; Soo, R. A.; Peters, S.; Tsourti, Z.; Vervita, K.; Han, J-Y.; De Castro, J.; Coate, L.; Frueh, M.; Hashemi, S. M. S.; Nadal, E.; Carcereny, E.; Sala Gonzalez, M. Angeles; Bernabe Caro, R.; Provencio Pulla, M.; Cuffe, S.; Ruepp, B.; Roschitzki-Voser, H.; Rosell, R.; Stahel, R. A.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

奥希替尼和贝伐单抗与单独奥希替尼作为二线靶向治疗的二线随机II期研究证实EGFR和获得性T790M突变的晚期NSCLC: 欧洲胸部肿瘤学平台 (ETOP 10-16) 加强试验

ANNALS OF ONCOLOGY
IF65.4
2022-02-0164
OAAI
Sooy, R. A.; Han, J. -Y.; Dafni, U.; Cho, B. C.; Yeo, C. M.; Nadal, E.; Carcereny, E.; de Castro, J.; Sala, M. A.; Bernabe, R.; Coate, L.; Provencio Pulla, M.; Campelo, R. Garcia; Cuffe, S.; Hashemi, S. M. S.; Fruh, M.; Massuti, B.; Garcia-Sanchez, J.; Domine, M.; Majem, M.; Sanchez-Torres, J. -M.; Britschgi, C.; Pless, M.; Dimopoulou, G.; Roschitzki-Voser, H.; Ruepp, B.; Rosell, R.; Stahel, R. A.; Peters, S.

研究方向

暂未获取到该数据
E
Egbert F. Smit
H 指数:113论文数:1,213被引数:6.0万
L
Lizza Hendriks
H 指数:48论文数:432被引数:1.0万
I
Idris Bahce
H 指数:31论文数:189被引数:4,706
S
Suresh Senan
H 指数:95论文数:831被引数:4.1万
A
Anthonie J. van der Wekken
H 指数:29论文数:192被引数:4,518
C
Chris Dickhoff
H 指数:21论文数:172被引数:1,559
A
Anne‐Marie C. Dingemans
H 指数:71论文数:674被引数:2.0万
F
Famke L. Schneiders
H 指数:15论文数:92被引数:1,195
K
Kim Monkhorst
H 指数:41论文数:391被引数:7,506
J
Johannes M. A. Daniels
H 指数:38论文数:226被引数:4,520